| 中文名称: | 布帕伐醌 | ||||
|---|---|---|---|---|---|
| 英文名称: | Buparvaquone | ||||
| 别名: | 布帕伐醌 Buparvaquone;3-[(4-tert-butylcyclohexyl)methyl]-4-hydroxynaphthalene-1,2-dione;2-((4-tert-Butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthochinon;Buparvacuona [Spanish];Buparvaquonum [Latin];Butalex;BW 720C;UNII-0354RT7LG4 | ||||
| CAS No: | 88426-33-9 | 分子式: | C21H26O3 | 分子量: | 326.43 |
| CAS No: | 88426-33-9 | ||||
| 分子式: | C21H26O3 | ||||
| 分子量: | 326.43 | ||||
基本信息
|
产品编号：B10552 |
|||||
|
产品名称：Buparvaquone |
|||||
|
CAS: |
88426-33-9 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
分子式： |
溶于液体 |
-80℃ |
两年 |
||
|
分子量 |
326.43 |
|
|
||
|
化学名： |
2-((4-(1,1-Dimethylethyl)cyclohexyl)methyl)-3-hydroxy-1,4-naphthalenedione |
||||
|
Solubility (25°C) |
体外 |
DMSO |
65mg/mL (199.12mM) |
||
|
Ethanol |
4mg/mL (12.25mM) |
||||
|
Water |
Insoluble |
||||
|
体内 |
现配现用 |
|
|||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
3.0634mL |
15.3172mL |
30.6344mL |
|
5mM |
0.6127mL |
3.0634mL |
6.1269mL |
|
10mM |
0.3063mL |
1.5317mL |
3.0634mL |
|
50mM |
0.0613mL |
0.3063mL |
0.6127mL |
生物活性
|
产品描述 |
一种与parvaquone和atovaquone有关的羟基萘醌类抗原虫药。 |
|
|
靶点/IC50 |
Parasite |
Antibiotic |
|
体外研究 |
In 4-day proliferation assays, buparvaquone efficiently inhibits N. caninum tachyzoite replication(IC50=4.9nM; IC100=100nM). Buparvaquone is significantly selective against L. (L.) infantum chagasi intracellular amastigotes, with an IC50 value of 1.5μM. Other cutaneous species are also susceptible to buparvaquone, with IC50 values in the range 1-4μM. |
|
|
体内研究 |
Treatment of N. caninum infected mice with buparvaquone (100mg/kg) either by intraperitoneal injection or gavage prevents neosporosis symptoms in 4 out of 6 mice in the intraperitoneally treated group, and in 6 out of 7 mice in the group receiving oral treatment. Both a hydrous gel and water-in-oil emulsion of buparvaquone significantly reduce cutaneous parasite burden and lesion size, compared with the untreated control. |
|
推荐实验方法(仅供参考)
|
细胞实验: |
|
|
Cell Assay |
To study whether pretreatment of host cells prior to invasion had any effect on parasite proliferation, confluent HFF grown in 6-well plates are treated with 1µM buparvaquone in medium for 1 h or 5h, and controls are exposed to the corresponding amounts of DMSO. Subsequently, the drug-containing medium is removed and monolayers are ished 4 times with Hank's Balanced Salt Solution, and are infected with Nc-Liv tachyzoites in 5mL medium without any drug or solvent.After 2 days, cells are collected with a cell scraper, centrifuged, ished once more in PBS, and the pellet is stored at −20 °C prior to quantification of N. caninum proliferation by N. caninum-specific real time PCR as outlined below. |
|
动物实验: |
|
|
Animal Administration |
Mice: On day 0, all mice are infected by intraperitoneal (i.p.) injection of freshly purified N. caninum tachyzoites. After 48h,mice receive BPQ (100 mg/kg) as suspension in corn oil either by i.p. injection of a volume of 100 µl or by oral application of 100µl by gavage. The control groups obtained the corresponding amount of the solvent only, either i.p. or orally (see Table 2). The treatments are performed 5 times on a daily basis. If not indicated otherwise, mice are inspected twice daily for clinical signs (ruffled coat, apathy, hind limb paralysis) until day 21 post infection (p.i.), at which time they are euthanized. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
